Global Health Limited Q1 FY27 Earnings Call Summary

Event Participants

Executives

4 Gaurav Chugh, Naresh Trehan, Pankaj Sahni, Yogesh Kumar Gupta

Analysts

7 Abdulkader Puranwala, Amey Chalke, Parth Sodha, Raman K.V., Sucrit Patil, Tushar Manudhane, Vivek

Financials & KPIs

Geographic & Segment Commentary

• Cluster 1 (Gurugram, Indore, Ranchi): Revenue ₹771.5 crores (+10% YoY); EBITDA ₹185.8 crores (+13%) with margin improving to 24.1% from 23.4%; IP volumes +14%, ARPOB +7%; ALOS improved to 2.8 days; occupancy stable at 63%; ARPP ₹290,623 broadly flat. Brownfield additions in progress: 100 beds at Ranchi operationalized last fiscal, 80-bed Indore acquisition due end Q2/early Q3 FY27, and Gurgaon adding procedural capacity (2 OTs and 2-3 cath labs in Q2).
• Cluster 2 (Lucknow, Patna, Noida): Total income ₹498.3 crores (+55% YoY); EBITDA ₹127.2 crores (+35%); ex-Noida revenue +28% and EBITDA +40% at a strong 32% margin; IP volumes +50%, OBD +44%; ARPOB +9% to ₹61,742; ARPP ₹182,407 (+5%); occupancy 62% vs 64% YoY, marginally lower due to phased Noida capacity additions. Lucknow and Patna continue growing 20%+ on volumes alone with no tariff increases.
• Medanta Noida: Income ₹85.5 crores vs ₹52.5 crores in Q4 FY26; EBITDA loss cut to ₹4.9 crores from ₹23.6 crores; 51 beds added in the quarter; major empanelments with insurance, PSU, and corporates completed; all major specialties operational except liver transplant; management expects EBITDA breakeven earlier than previously guided.
• Guwahati (under development): Project expanded to a 650-bed super-specialty hospital with estimated cost of ~₹970 crores; revised building bylaws and National Building Code 2026 enabled ~60,000 sq ft floor plates and doubled procedure areas (28-30 OTs, doubled cath labs and LINACs); construction commencing with approvals largely in place.

Company-Specific & Strategic Commentary

• Talent & Clinical Depth: Onboarded 70+ doctors in Q1 including 50+ senior clinicians; senior clinical attrition described as negligible over the last 6-18 months; Lucknow crossed 1,000 robotic joint replacements.
• Technology & Procedural Capacity: Continued investment in LINACs, advanced CT/MR diagnostics, and robotic platforms (soft tissue and orthopedic) across the network; Noida fully equipped with 14 OTs, radiation oncology, robot, and O-arm; Gurgaon OT count to reach ~44-45 with Q2 additions.
• Noida Ramp-up: Ahead of internal expectations; bed base growing 30-40% quarter-on-quarter; empanelments secured across insurance, PSU, and corporate segments; management confident of earlier-than-planned EBITDA breakeven.
• Guwahati Project Expansion: Scaled from ~400 to 650 beds with ~₹970 crores project cost; National Building Code 2026 changes doubled floor plate (from ~30-40k to ~60k sq ft) and operating rooms (from ~13-14 to 28-30), plus doubled cath labs and LINACs; additional FSI obtained at no land cost.
• Retail Pharmacy & Continuity of Care: OPD pharmacy revenue +51% YoY; 13 retail pharmacies operating; positioned as an extension of care within existing hospital catchments (UP, Bihar); steady, not exponential, scaling expected.
• Disclosure Enhancements: Introduced ARPP as an additional operating metric; renamed mature/developing hospitals as Cluster 1/Cluster 2 (composition unchanged).

Guidance & Outlook

Risks & Constraints

Q&A Highlights

Execution Priorities & Financial Risk Management

• Question: What are the top 2-3 execution priorities and key risks to margins, cash flow, and balance sheet? (Sucrit Patil - Eyesight Fintrade)
• Answer: (Pankaj Sahni) Priorities remain consistent: clinical/operating excellence across all six hospitals; Noida ramp-up (ahead of internal expectations); continued clinical talent additions and technology investment (LINACs, CT/MR, robotic equipment); Indore 80-bed addition and cancer services scale-up in Ranchi/Indore; retail pharmacy/lab scaling. (Yogesh Gupta) Margins stable with continuous cost focus on material, manpower, and other costs; cash flow generation strong and funding growth through internal accruals plus debt/equity; low leverage, no balance sheet challenges.

Margin Trajectory as Noida Matures

• Question: Will consolidated EBITDA margin move back toward the FY25-26 range or stay around current levels? (Parth Sodha - Trinetra Asset Managers)
• Answer: Management does not give margin guidance. Reported margin is already ~24% including Noida's ₹4.9 crore loss; ex-Noida margin is ~26%. No significant structural cost additions are expected; margins should benefit from operating leverage as Noida losses reverse.

Expansion Capex & Tier 2/3 Government Policy

• Question: How much of the 2,950-bed expansion capex is already incurred? Will revised government policy expedite Guwahati and Varanasi timelines? (Abdulkader Puranwala - ICICI Securities)
• Answer: (Yogesh Gupta) ₹4,850 crores is the future capex requirement; ₹161 crores was incurred in Q1; completed spend is already reflected in the balance sheet. (Pankaj Sahni) Any policy supporting Tier 2/3 hospital setup is welcome, but it has no impact on Guwahati - approvals are largely in place and construction is already commencing.

Oncology Mix & CGHS Revision

• Question: Oncology revenue share dipped ~70 bps YoY to 13.5% - is this due to the CGHS revision? (Abdulkader Puranwala - ICICI Securities)
• Answer: (Pankaj Sahni) No pricing impact - cancer revenue actually grew. Surgical cancers are reported under respective specialties (urology, GI, ortho), and quarterly seasonality affects the specialty mix; an annual view is more meaningful. CGHS is only ~10-12% of revenue; the October hike is fully captured but not needle-moving since growth is volume-led.

Noida Occupancy, Fixed Costs & Specialty Coverage

• Question: What is Noida's occupancy level, will fixed costs increase, and are all specialties operational? (Amey Chalke - JM Financial)
• Answer: Occupancy is roughly 30-40% but misleading given continuous bed additions (30-40% QoQ bed growth). All major specialties are operational except liver transplant; high-end equipment (14 OTs, radiation oncology, robot, O-arm) is already installed; no significant incremental capex is planned near-term.

Noida-Gurgaon Referral Dynamics

• Question: Are Gurgaon referrals helping Noida scale faster? (Amey Chalke - JM Financial)
• Answer: (Pankaj Sahni) Coordination is network-wide (Lucknow→Gurgaon, Gurgaon→Patna, etc.); patients who cannot easily access Gurgaon due to distance now have Noida as an option. Several Noida department heads - cardiac surgery, chest surgery, plastic surgery, critical care - moved from Gurgaon, bringing established training and experience.

Volume Growth Sustainability & Demand Tailwinds

• Question: What is ex-Noida IPD growth, and is 20%+ volume growth a safe assumption? Any specific demand shifts? (Tushar Manudhane - Motilal Oswal)
• Answer: Ex-Noida Cluster 2 IPD growth is ~27%; Lucknow and Patna have consistently grown 20%+ with zero tariff increases; Gurgaon still delivers 7-10% volume growth at ~1,500 beds. The Guwahati announcement has already increased northeast patient flow to Gurgaon. India's healthcare demand is strong - "our real challenge is delivering supply, not demand."

Clinical Attrition & Retail Pharmacy Strategy

• Question: What are attrition rates at the network level, and how should retail pharmacy scale? (Tushar Manudhane - Motilal Oswal)
• Answer: Senior clinical attrition has been negligible over the last 6-18 months; nursing and junior doctor attrition is high but industry-wide. Retail pharmacy/labs are an extension of Medanta's care ecosystem beyond hospital walls; 13 pharmacies currently, scaling steadily within existing catchments (UP, Bihar) - pace may move from ~10 to 15-20 per quarter, but no jump to 100-200 in the next 4-6 quarters.

Gurgaon vs Lucknow Growth Differentials

• Question: Why can't Gurgaon replicate Lucknow-level growth? (Vivek - Emkay Global)
• Answer: (Pankaj Sahni) Different lifecycles and demographics: a 15-year-old, ~1,500-bed hospital running near-full versus a 5-6-year-old, ~750-bed facility; Eastern UP has a population base of 100 million+ versus a much smaller NCR catchment. Lucknow's growth has been exceptional by industry standards, not a benchmark; Gurgaon growing double-digit volumes at scale is rare. Medanta is the only major listed chain consistently growing double-digit on volume rather than tariff.

Guwahati CapEx per Bed Rationale

• Question: Why did the revised Guwahati plan raise capex by ~₹500 crores for 250 incremental beds? (Vivek - Emkay Global)
• Answer: (Pankaj Sahni) Beds alone is the wrong lens - National Building Code 2026 changes doubled the floor plate (from ~30-40k to ~60k sq ft); operating rooms more than doubled from ~13-14 to 28-30; cath labs and LINACs doubled; built-up area increased from ~6.5 lakh to ~9.8 lakh sq ft. Additional FSI was obtained at no cost on the same land; capex reflects procedure areas, not just bed count.

Cluster Margin Differentials & Brownfield Expansion

• Question: Is Cluster 1's growth slowdown due to capacity constraints? Will Cluster 2 sustain 30% margins and can Noida reach 30%? (Raman K.V. - Sequent Investments)
• Answer: (Pankaj Sahni) Cluster 1 grew 10% on a very large base; brownfield additions include 100 beds at Ranchi (last FY), 80 beds at Indore (end Q2/early Q3), and procedural capacity at Gurgaon (OTs, cath labs). On margins: no guidance; Cluster 1 carries full corporate overheads, while newer units benefit from equipment under warranty and more efficient manpower structures; there is no structural difference in the work mix. Noida operating leverage should be margin-accretive; margins should remain stable or grow.

Key Takeaway

Global Health (Medanta) delivered a strong Q1 FY27 with consolidated income of ₹1,326.2 crores (+26% YoY) and reported EBITDA of ₹315.3 crores (23.8% margin); PAT of ₹157.3 crores was flat YoY solely due to a ₹19.6 crore one-time gain in the base quarter. Growth remained volume-led, with IP volumes +28%, OP volumes +34%, and ARPOB up 5% to ₹70,244. Medanta Noida was the standout - income jumped to ₹85.5 crores and EBITDA loss narrowed to ₹4.9 crores from ₹23.6 crores in Q4 FY26, with management guiding to EBITDA breakeven earlier than expected. Cluster 2 ex-Noida grew revenue 28% at 32% EBITDA margins, while Cluster 1 grew 10% with margins improving to 24.1%. Strategically, the company onboarded 70+ doctors, expanded Guwahati to 650 beds (~₹970 crores), and maintains a ~3,350-bed pipeline backed by ₹4,850 crores of future capex. Watch points include Noida's ramp-up sustainability, geopolitical effects on international patients, and execution of the large expansion pipeline.